AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
AstraZeneca PLCNYSE: AZN
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows in line with its trailing trend
Q3 FY2026 revenue of $15.99B rose 5.3% year over year, behind the +7.0% change in trailing-twelve-month revenue. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 18 analysts of $62.71B (+6.8%) for the fiscal year ending Dec 2026, a slowdown from the +8.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $15.99B+4.0% QoQ
- Last fiscal yearDec 2025
- $58.74B+8.6% YoY
- LTMSep 2026
- $62.17B+7.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.3% | +7.2% | +1.9 pp |
| 1 year | +8.6% | +6.8% | -1.9 pp |
| 3-year CAGR | +9.8% | +6.5% | -3.4 pp |
| 5-year CAGR | +6.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 58.74B USD
- Year-over-year change
- +8.6%
- 4-year CAGR
- +11.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.74B | +8.6% |
| FY2024 | 2024-12-31 | 54.07B | +18.0% |
| FY2023 | 2023-12-31 | 45.81B | +3.3% |
| FY2022 | 2022-12-31 | 44.35B | +18.5% |
| FY2021 | 2021-12-31 | 37.42B | — |
Revenue vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +7.0% is the 5th highest of 10, against a peer median of +5.6%.
- Over three fiscal years its annual growth of +9.8% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | DKK 329.43B DKK | +5.6% | +20.4% | |
| LTM Sep 2026 | $99.34B USD | +7.8% | +5.6% | |
| LTM Jun 2026 | $79.67B USD | +49.6% | +31.7% | |
| LTM Jun 2026 | $66.4B USD | +4.2% | +3.1% | |
| LTM Sep 2026 | $66.01B USD | +10.7% | +1.8% | |
| LTM Jun 2026 | $63.7B USD | -0.2% | -14.8% | |
| LTM Sep 2026 | $62.17B USD | +7.0% | +9.8% | |
| LTM Jun 2026 | $55.63B USD | +0.8% | +8.0% | |
| LTM Jun 2026 | $49.19B USD | +3.1% | +1.4% | |
| LTM Jun 2026 | $38.13B USD | +9.2% | +11.8% | |
| Peer median (excluding AZN) | — | +5.6% | +5.6% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.42B | 44.35B | 45.81B | 54.07B | 58.74B |
| Cost of Revenue | 12.44B | 12.39B | 8.27B | 10.21B | 10.63B |
| Gross Profit | 24.98B | 31.96B | 37.54B | 43.87B | 48.11B |
| Gross Margin | 66.8% | 72.1% | 82.0% | 81.1% | 81.9% |
| Research & Development | 9.74B | 9.76B | 10.94B | 13.58B | 14.23B |
| Selling, General & Admin | 15.59B | 17.98B | 18.22B | 20.22B | 20.51B |
| Operating Expenses | 23.92B | 28.2B | 29.35B | 33.86B | 34.36B |
| Depreciation & Amortization | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B |
| EBITDA | 5.11B | 9.09B | 13.42B | 15.44B | 19.83B |
| EBITDA Margin | 13.7% | 20.5% | 29.3% | 28.6% | 33.8% |
| Operating Income | 1.06B | 3.76B | 8.19B | 10B | 13.74B |
| Operating Margin | 2.8% | 8.5% | 17.9% | 18.5% | 23.4% |
| Interest Income | 43M | 81M | 301M | 345M | 360M |
| Interest Expense | 1.28B | 1.33B | 1.59B | 1.68B | 1.69B |
| Other Income / Expenses | (1.32B) | (1.26B) | (1.29B) | (1.31B) | (1.34B) |
| Income Before Tax | (265M) | 2.5B | 6.9B | 8.69B | 12.4B |
| Pre-Tax Margin | -0.7% | 5.6% | 15.1% | 16.1% | 21.1% |
| Income Tax Expense | (380M) | (792M) | 938M | 1.65B | 2.17B |
| Net Income | 112M | 3.29B | 5.96B | 7.04B | 10.26B |
| Net Margin | 0.3% | 7.4% | 13.0% | 13.0% | 17.5% |
| EPS (Basic) | 0.08 | 2.12 | 3.81 | 4.54 | 6.60 |
| EPS (Diluted) | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 |
| Weighted Avg Shares | 1.42B | 1.55B | 1.56B | 1.55B | 1.55B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.56B | 1.56B | 1.56B | 1.56B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.